TrialDiabetes2013

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.

William Hagopian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.